What is he best known for?
The fields of study he is best known for:
His primary areas of investigation include Zinc finger, Genetics, DNA, Protein–DNA interaction and Zinc finger nuclease.
His Zinc finger research incorporates elements of Protein structure, Protein engineering and Phage display.
His Genetics study frequently links to other fields, such as Computational biology.
His DNA research is classified as research in Biochemistry.
His work deals with themes such as DNA-binding domain, LIM domain and RING finger domain, which intersect with Protein–DNA interaction.
David J. Segal works mostly in the field of Zinc finger nuclease, limiting it down to concerns involving Homologous recombination and, occasionally, Cleavage.
His most cited work include:
- TLR3 deficiency in patients with herpes simplex encephalitis. (839 citations)
- Endorphins: profound behavioral effects in rats suggest new etiological factors in mental illness. (754 citations)
- Stimulation of homologous recombination through targeted cleavage by chimeric nucleases. (533 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of study are Zinc finger, Genetics, Computational biology, DNA and Cancer research.
His study in Zinc finger is interdisciplinary in nature, drawing from both Molecular biology and DNA sequencing.
His Computational biology study integrates concerns from other disciplines, such as Genome editing, Cas9, CRISPR, RNA and Binding domain.
David J. Segal interconnects Cell culture, Apoptosis, MCL1, Leukemia and Multiple myeloma in the investigation of issues within Cancer research.
His research integrates issues of Myeloid Cell Leukemia Sequence 1 Protein, Cancer and Pharmacology in his study of MCL1.
His study looks at the relationship between Zinc finger nuclease and topics such as Homologous recombination, which overlap with Endonuclease.
He most often published in these fields:
- Zinc finger (31.22%)
- Genetics (28.29%)
- Computational biology (22.93%)
What were the highlights of his more recent work (between 2017-2021)?
- Cancer research (24.39%)
- Computational biology (22.93%)
- CRISPR (7.80%)
In recent papers he was focusing on the following fields of study:
His scientific interests lie mostly in Cancer research, Computational biology, CRISPR, Gene and Genome editing.
His Cancer research research includes themes of Cell culture, Apoptosis, Bortezomib, Venetoclax and MCL1.
In his study, which falls under the umbrella issue of MCL1, Chemotherapy and Pharmacology is strongly linked to Leukemia.
His Gene study is associated with Genetics.
His Cas9 research is multidisciplinary, relying on both Protein engineering, Comparative genomics and Zinc finger, Artificial transcription factor.
He has researched Zinc finger in several fields, including Sequence and Function.
Between 2017 and 2021, his most popular works were:
- Targeted DNA demethylation of the Arabidopsis genome using the human TET1 catalytic domain (89 citations)
- Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1 (77 citations)
- Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1 (77 citations)
In his most recent research, the most cited papers focused on:
David J. Segal mostly deals with Cancer research, Regulation of gene expression, MCL1, Myeloid and Venetoclax.
He has included themes like Arthritis, Inflammation, Interferon, Ikaros Transcription Factor and Programmed cell death in his Cancer research study.
His studies deal with areas such as Cell, Apoptosis, Transcription factor, Downregulation and upregulation and IKZF3 as well as Regulation of gene expression.
His MCL1 study combines topics in areas such as Cytarabine, Leukemia, Myeloid leukemia, Chemotherapy and Pharmacology.
His Myeloid research is multidisciplinary, incorporating elements of Myeloid Cell Leukemia Sequence 1 Protein, Idarubicin, Hematology and Bone marrow.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
